Publications 2025

Ramberg H, Zucknick M, Barletta F, Davik P, Nybøen Å, Eri LM, Sivanesan S, Hole KH, Hompland T, Prestbakk SO, Gandaglia G, Bathen TF, Briganti A, Berge V, Austild Tasken K (2025)
Development and evaluation of a lymph node invasion risk prediction model in intermediate- and high-risk prostate cancer patients
Acta Oncol, 64, 1446-1454
DOI 10.2340/1651-226X.2025.43970, PubMed 41123130

Skipar K, Hompland T, Lund KV, Fjeldbo CS, Lindemann K, Hellebust TP, Lyng H, Bruheim K (2025)
Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: A phase II, randomized study
Acta Oncol, 64, 439-447
DOI 10.2340/1651-226X.2025.43045, PubMed 40105683

Switlyk MD, Dale E, Tafjord S, Willumsen L, Hole KH, Hompland T (2025)
Reduced field-of-view DWI outperforms conventional DWI in assessing tumor heterogeneity and HPV status in head and neck cancer
Sci Rep, 15 (1), 31889
DOI 10.1038/s41598-025-17284-8, PubMed 40883428

Publications 2024

Fernandez Salamanca M, Hompland T, Deręgowska-Cylke M, Van der Poel H, Bekers E, Guimaraes MAS, Lyng H, Van der Heide UA, Schoots IG, Van Houdt PJ (2024)
A DWI-based hypoxia model shows robustness in an external prostatectomy cohort
Front Oncol, 14, 1433197
DOI 10.3389/fonc.2024.1433197, PubMed 39109282

Marsilla J, Weiss J, Ye XY, Welch M, Milosevic M, Lyng H, Hompland T, Bruheim K, Tadic T, Haibe-Kains B, Han K (2024)
A T2-weighted MRI-based radiomic signature for disease-free survival in locally advanced cervical cancer following chemoradiation: An international, multicentre study
Radiother Oncol, 199, 110463
DOI 10.1016/j.radonc.2024.110463, PubMed 39067707

Skingen VE, Salberg UB, Hompland T, Fjeldbo CS, Helgeland H, Frikstad KM, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2024)
Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer
J Pathol, 264 (3), 270-283
DOI 10.1002/path.6344, PubMed 39329425

Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H (2024)
MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
Radiother Oncol, 195, 110263
DOI 10.1016/j.radonc.2024.110263, PubMed 38556173

Publications 2023

Leech M, Leijenaar RTH, Hompland T, Gaffney J, Lyng H, Marignol L (2023)
Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring
Anticancer Res, 43 (1), 351-357
DOI 10.21873/anticanres.16170, PubMed 36585179

Mo T, Brandal SHB, Geier OM, Engebråten O, Nilsen LB, Kristensen VN, Hole KH, Hompland T, Fleischer T, Seierstad T (2023)
MRI Assessment of Changes in Tumor Vascularization during Neoadjuvant Anti-Angiogenic Treatment in Locally Advanced Breast Cancer Patients
Cancers (Basel), 15 (18)
DOI 10.3390/cancers15184662, PubMed 37760629

Skingen VE, Hompland T, Fjeldbo CS, Salberg UB, Helgeland H, Ragnum HB, Aarnes EK, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2023)
Prostate cancer radiogenomics reveals proliferative gene expression programs associated with distinct MRI-based hypoxia levels
Radiother Oncol, 188, 109875
DOI 10.1016/j.radonc.2023.109875, PubMed 37640161

Publications 2022

Lyng H, Skipar K, Hompland T (2022)
Targeted Therapy on the Screen: Do We Hit the Target?
Clin Cancer Res, 28 (24), 5233-5234
DOI 10.1158/1078-0432.CCR-22-2707, PubMed 36240006

Mo T, Brandal SHB, Köhn-Luque A, Engebraaten O, Kristensen VN, Fleischer T, Hompland T, Seierstad T (2022)
Quantification of Tumor Hypoxia through Unsupervised Modelling of Consumption and Supply Hypoxia MR Imaging in Breast Cancer
Cancers (Basel), 14 (5)
DOI 10.3390/cancers14051326, PubMed 35267636

Nilsen A, Hillestad T, Skingen VE, Aarnes EK, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H (2022)
miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
Mol Oncol, 16 (6), 1402-1419
DOI 10.1002/1878-0261.13184, PubMed 35064630

Salberg UB, Skingen VE, Fjeldbo CS, Hompland T, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2022)
A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients
Br J Cancer, 127 (2), 321-328
DOI 10.1038/s41416-022-01782-x, PubMed 35332267

Sinno N, Taylor E, Hompland T, Milosevic M, Jaffray DA, Coolens C (2022)
Incorporating cross-voxel exchange for the analysis of dynamic contrast-enhanced imaging data: pre-clinical results
Phys Med Biol, 67 (24)
DOI 10.1088/1361-6560/aca512, PubMed 36541560

Skipar K, Hompland T, Lund KV, Løndalen A, Malinen E, Kristensen GB, Lindemann K, Nakken ES, Bruheim K, Lyng H (2022)
Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
Radiother Oncol, 176, 17-24
DOI 10.1016/j.radonc.2022.09.002, PubMed 36113778

Publications 2021

Hompland T, Fjeldbo CS, Lyng H (2021)
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Cancers (Basel), 13 (3)
DOI 10.3390/cancers13030499, PubMed 33525508

Publications 2020

Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H (2020)
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
EBioMedicine, 57, 102841
DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139

Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, Lyng H (2020)
MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
Cancer Res, 80 (18), 3993-4003
DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004

Publications 2018

Hompland T, Hole KH, Ragnum HB, Aarnes EK, Vlatkovic L, Lie AK, Patzke S, Brennhovd B, Seierstad T, Lyng H (2018)
Combined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients
Cancer Res, 78 (16), 4774-4785
DOI 10.1158/0008-5472.CAN-17-3806, PubMed 29945958

Simonsen TG, Lund KV, Hompland T, Kristensen GB, Rofstad EK (2018)
DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
Int J Radiat Oncol Biol Phys, 102 (4), 1193-1201
DOI 10.1016/j.ijrobp.2018.04.035, PubMed 29859790

Publications 2015

Lund KV, Simonsen TG, Hompland T, Kristensen GB, Rofstad EK (2015)
Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer
Radiother Oncol, 115 (3), 379-85
DOI 10.1016/j.radonc.2015.05.001, PubMed 25998804

Publications 2014

Hompland T, Ellingsen C, Galappathi K, Rofstad EK (2014)
DW-MRI in assessment of the hypoxic fraction, interstitial fluid pressure, and metastatic propensity of melanoma xenografts
BMC Cancer, 14, 92
DOI 10.1186/1471-2407-14-92, PubMed 24528854

Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK (2014)
Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
Radiother Oncol, 113 (1), 132-8
DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501

Publications 2013

Ellingsen C, Hompland T, Galappathi K, Mathiesen B, Rofstad EK (2013)
DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts
Radiother Oncol, 110 (2), 335-41
DOI 10.1016/j.radonc.2013.10.018, PubMed 24231244

Ellingsen C, Walenta S, Hompland T, Mueller-Klieser W, Rofstad EK (2013)
The Microenvironment of Cervical Carcinoma Xenografts: Associations with Lymph Node Metastasis and Its Assessment by DCE-MRI
Transl Oncol, 6 (5), 607-17
DOI 10.1593/tlo.13313, PubMed 24151541

Gaustad JV, Pozdniakova V, Hompland T, Simonsen TG, Rofstad EK (2013)
Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts
J Exp Clin Cancer Res, 32 (1), 93
DOI 10.1186/1756-9966-32-93, PubMed 24245934

Hompland T, Ellingsen C, Galappathi K, Rofstad EK (2013)
Connective tissue of cervical carcinoma xenografts: associations with tumor hypoxia and interstitial fluid pressure and its assessment by DCE-MRI and DW-MRI
Acta Oncol, 53 (1), 6-15
DOI 10.3109/0284186X.2013.773073, PubMed 23445339

Publications 2012

Ellingsen C, Hompland T, Mathiesen B, Rofstad EK (2012)
Microenvironment-associated lymph node metastasis of human cervical carcinoma xenografts
Acta Oncol, 51 (4), 465-72
DOI 10.3109/0284186X.2011.636751, PubMed 22292610

Hompland T, Ellingsen C, Rofstad EK (2012)
Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure
BMC Cancer, 12, 544
DOI 10.1186/1471-2407-12-544, PubMed 23173554

Hompland T, Ellingsen C, Øvrebø KM, Rofstad EK (2012)
Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI
Cancer Res, 72 (19), 4899-908
DOI 10.1158/0008-5472.CAN-12-0903, PubMed 23027087

Hompland T, Gulliksrud K, Ellingsen C, Rofstad EK (2012)
Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights
Acta Oncol, 52 (3), 627-35
DOI 10.3109/0284186X.2012.737931, PubMed 23126523

Øvrebø KM, Ellingsen C, Hompland T, Rofstad EK (2012)
Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of tumors: a preclinical study of cervical carcinoma and melanoma xenografts
Acta Oncol, 52 (3), 604-11
DOI 10.3109/0284186X.2012.689851, PubMed 22671573

Publications 2011

Gulliksrud K, Hompland T, Galappathi K, Rofstad EK (2011)
Assessment of tumor hypoxia and interstitial fluid pressure by gadomelitol-based dynamic contrast-enhanced magnetic resonance imaging
Radiother Oncol, 101 (1), 217-22
DOI 10.1016/j.radonc.2011.06.036, PubMed 21840612

Øvrebø KM, Hompland T, Mathiesen B, Rofstad EK (2011)
Assessment of hypoxia and radiation response in intramuscular experimental tumors by dynamic contrast-enhanced magnetic resonance imaging
Radiother Oncol, 102 (3), 429-35
DOI 10.1016/j.radonc.2011.11.013, PubMed 22197352

Publications 2008

Hompland T, Erikson A, Lindgren M, Lindmo T, de Lange Davies C (2008)
Second-harmonic generation in collagen as a potential cancer diagnostic parameter
J Biomed Opt, 13 (5), 054050
DOI 10.1117/1.2983664, PubMed 19021430

Publications 2007

Erikson A, Ortegren J, Hompland T, de Lange Davies C, Lindgren M (2007)
Quantification of the second-order nonlinear susceptibility of collagen I using a laser scanning microscope
J Biomed Opt, 12 (4), 044002
DOI 10.1117/1.2772311, PubMed 17867806